Држава: Канада
Језик: Енглески
Извор: Health Canada
BUPIVACAINE HYDROCHLORIDE
STERIMAX INC
N01BB01
BUPIVACAINE
7.5MG
SOLUTION
BUPIVACAINE HYDROCHLORIDE 7.5MG
RETROBULBAR
15G/50G
Ethical
LOCAL ANESTHETICS
Active ingredient group (AIG) number: 0108896002; AHFS:
APPROVED
2020-09-11
_ _ _Bupivacaine Hydrochloride Injection, USP Product Monograph Page 1 of 35_ PRODUCT MONOGRAPH BUPIVACAINE HYDROCHLORIDE INJECTION, USP 2.5 mg/mL, 5 mg /mL and 7.5 mg/mL Bupivacaine Hydrochloride, USP Sterile Solution Local Anesthetic STERIMAX INC. Oakville, Ontario 2770 Portland Drive L6H 6R4 Date of Preparation: September 8, 2020 Submission Control No: 238228 _ _ _Bupivacaine Hydrochloride Injection, USP Product Monograph Page 2 of 35_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................. 10 DRUG INTERACTIONS ................................................................................................. 13 DOSAGE AND ADMINISTRATION ............................................................................. 14 OVERDOSAGE ............................................................................................................... 18 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 21 STORAGE AND STABILITY ......................................................................................... 23 SPECIAL HANDLING INSTRUCTIONS ...................................................................... 24 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................ 24 PART II: SCIENTIFIC INFORMATION .............................................................................. 26 PHARMACEUTICAL INFORMATION ................................. Прочитајте комплетан документ